Dipna Pharmachem Ltd (DPL)

Loading page…

Dipna Pharmachem Ltd (DPL) · mywealthgrid

About

Dipna Pharmachem Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹11 Cr

P/E

4.2×

P/B

0.2×

Dividend yield

ROE

5.3%

ROCE

8.2%

Debt / equity

0.21

OPM

3.9%

EPS (TTM)

₹1.0

Book value

₹23.7

52-week high

—

52-week low

—

967 historical price candles were omitted because the exchange source has not been verified.

₹4.2-8.2%1Y

Quick read

rule-based

Pros

+Profit CAGR of 42.4% over the last 3 years

Cons

−Low return on equity of 4.2% (3-yr avg)
−Thin operating margin of 3.9%
−Modest revenue growth of 8.9% a year over the last 3 years
−Low promoter holding of 9.1%

Research score

Structured signal from quality, growth, valuation and momentum.

64/100

Business quality: 24
Growth: 68
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	100	164	125	129
COGS	95	158	114	107
Gross profit	4	6	11	22
	2	3	8	17
	2	3	3	5
OPM %	2.4%	2.1%	2.8%	3.9%
Depreciation	0	0	0	0
Interest	1	2	2	1
	0	0	0	0
Profit before tax	1	1	1	4
Tax	0	0	0	1
Tax %	34.1%	23.2%	31.7%	25.7%
	1	1	1	3
PAT margin %	0.9%	0.7%	0.8%	2%
EPS (₹)	0.8	0.9	0.4	1
EPS adjusted (₹)	0.8	0.5	—	1
Annual report	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	12	24	—	26
Reserves	12	13	—	36
	16	19	—	13
	37	76	132	130
Total equity & liabilities	78	133	132	206
	—	—	0	0
CWIP	—	—	—	0
Investments	0	0	0	0
	78	133	132	206
Total assets	78	133	132	206

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-21	-5	-9	-18
	-0	-0	-0	-0
	26	14	-4	19
Net cash flow	5	8	-13	0
Free cash flow	-21	-5	-9	-18
CFO / Operating profit %	-892.8%	-157.6%	-267.2%	-367.1%

Compounded sales growth

7 years: —
5 years: —
3 years: 9%
1 year: 3%

Compounded profit growth

7 years: —
5 years: —
3 years: 42%
1 year: 171%

Return on equity

7 years: —
5 years: —
3 years: 4%
Last year: 4%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	4.4%	3.9%	9%	16.7%
EBITDA margin %	2.4%	2.1%	2.8%	3.9%
EBIT margin %	2.3%	2.1%	2.7%	3.9%
PAT margin %	0.9%	0.7%	0.8%	2%
Working capital
Receivable days	104	69	—	136
Inventory days	72	86	88	144
Payable days	139	172	—	375
NWC days	38	-17	—	-95
Leverage
Current ratio	1.99	1.6	1.56	1.16
Debt to EBITDA	6.77	5.65	—	2.65
Debt to equity	0.65	0.52	—	0.21
Interest coverage	2.4	1.7	1.7	3.4
Asset turnover	1.29	1.24	0.94	0.63
Return ratios
Return on assets %	1.2%	0.8%	0.7%	1.3%
Return on capital employed %	6.1%	7.7%	7.1%	8.4%
Return on equity %	3.7%	2.9%	—	4.2%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2024	Mar 2025	Sep 2025	Mar 2026	Jun 2026
	9.98%	9.98%	9.98%	9.13%	9.13%
FII	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%
	90.02%	90.02%	90.02%	90.87%	90.87%
No. of shareholders	2,652	1,997	1,742	1,717	1,788

Promoter holding down 0.85 percentage points since Sep 2024.

1 deal · 14 Aug 2026 – 14 Aug 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
14 Aug 2026	HRIDAY AATISH SHAH	Bulk	BSE	Buy	1,50,000	₹5.70	₹0.09 Cr

1–1 of 1

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. Keyur Dipakkuamr ShahExecutive Director-Chairperson-MD
Mr. Jitendra Pradipbhai ParmarNon - Executive Independent Director
Mrs. Dipna Keyur ShahNon-Executive - Non Independent Director
Mr. Manish Shrichand BachaniNon - Executive Independent Director
Mr. Jitendra Pradipbhai ParmarNon-Executive - Independent Director
Mr. Manish Shrichand BachaniNon-Executive - Independent Director

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Dipna Pharmachem Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Intimation of Closure of Trading Window30 Sept 2026 · Closure of Trading Window

Annual reports

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

No events on record

Corporate actions, results dates and filings will appear here once ingested.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

1 announcementsExport CSV

30 Sept 2026, 5:01 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

Date	Category	Subject	Filing
30 Sept 2026, 5:01 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF

Loading announcements…

Ratio	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	4.4%	3.9%	9%	16.7%
EBITDA margin %	2.4%	2.1%	2.8%	3.9%
EBIT margin %	2.3%	2.1%	2.7%	3.9%
PAT margin %	0.9%	0.7%	0.8%	2%
Working capital
Receivable days	104	69	—	136
Inventory days	72	86	88	144
Payable days	139	172	—	375
NWC days	38	-17	—	-95
Leverage
Current ratio	1.99	1.6	1.56	1.16
Debt to EBITDA	6.77	5.65	—	2.65
Debt to equity	0.65	0.52	—	0.21
Interest coverage	2.4	1.7	1.7	3.4
Asset turnover	1.29	1.24	0.94	0.63
Return ratios
Return on assets %	1.2%	0.8%	0.7%	1.3%
Return on capital employed %	6.1%	7.7%	7.1%	8.4%
Return on equity %	3.7%	2.9%	—	4.2%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Dipna Pharmachem Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

No events on record

Announcements

Ratio timeline

No events on record

Quarterly record

Bulk & block deals

Board and management

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity